SIMPONI is designed for patients who have had an inadequate response to other therapies or who may be intolerant to medicines used in conventional therapies.
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion, and a final decision from the European Commission is expected before the end of the year.
If approved, SIMPONI would be the only biologic therapy available for this patient population.
More Articles on Gastroenterology:
New York Gastroenterology Associates Opens Scarsdale Office
Study: Propofol Sedation for Colonoscopy Not Worth High Cost
South Carolina Medical Endoscopy System Adopts New Colonoscopy Screening Tool
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
